tiprankstipranks
Trending News
More News >
Euroapi SA (FR:EAPI)
:EAPI
France Market
Advertisement

Euroapi SA (EAPI) AI Stock Analysis

Compare
11 Followers

Top Page

FR:EAPI

Euroapi SA

(EAPI)

Rating:50Neutral
Price Target:
€3.00
▲(2.04%Upside)
Euroapi SA's overall stock score reflects its financial challenges, particularly in profitability and revenue growth, and poor valuation metrics due to a negative P/E ratio. The technical analysis provides a slightly more positive outlook, with stock prices above certain moving averages and a neutral RSI. Continued focus on improving financial performance and profitability will be essential for enhancing the stock's attractiveness.

Euroapi SA (EAPI) vs. iShares MSCI France ETF (EWQ)

Euroapi SA Business Overview & Revenue Model

Company DescriptionEuroapi SA (EAPI) is a leading European player in the pharmaceutical sector, specializing in the development, production, and supply of active pharmaceutical ingredients (APIs). The company operates across a broad spectrum of therapeutic areas, providing high-quality APIs that are essential components in the manufacturing of medicines. Euroapi serves a diverse range of clients, including pharmaceutical and biotechnology companies, across both generic and branded drug markets.
How the Company Makes MoneyEuroapi SA generates revenue primarily through the sale of active pharmaceutical ingredients (APIs) to pharmaceutical and biotechnology companies. The company's key revenue streams include long-term supply agreements with major pharmaceutical firms, custom manufacturing services, and the development of proprietary APIs. Euroapi leverages its extensive manufacturing capabilities, research and development expertise, and strong industry relationships to maintain a competitive edge. Strategic partnerships and collaborations with leading pharmaceutical companies further enhance its market presence and contribute significantly to its earnings.

Euroapi SA Financial Statement Overview

Summary
Euroapi SA faces financial challenges with declining revenue and profitability issues. Despite a positive EBITDA margin and efficient cash flow generation, the negative revenue growth and net losses weigh heavily on the financial performance score. The balance sheet shows low leverage and a strong equity position, providing a base for potential recovery.
Income Statement
42
Neutral
Euroapi SA has faced declining revenue over the past year, with a negative revenue growth rate of 9.78% from 2023 to 2024. The company is experiencing significant challenges in profitability, as indicated by negative EBIT and net profit margins. The gross profit margin also reflects a downward trend. Despite these challenges, the company has managed to maintain a positive EBITDA margin, offering some stability in operational performance.
Balance Sheet
55
Neutral
The balance sheet shows a moderate level of stability with a debt-to-equity ratio of 0.07, indicating low leverage. The return on equity is negative due to net losses, but the equity ratio remains healthy at 66.01%, suggesting a strong capital base. The company has been reducing its debt, which is a positive sign for future financial flexibility.
Cash Flow
50
Neutral
Euroapi SA's cash flow remains a mixed picture with a significant improvement in operating cash flow from 2023 to 2024. However, the free cash flow growth rate is negative, reflecting high capital expenditures. The operating cash flow to net income ratio is positive, indicating efficient cash generation relative to net income, but the free cash flow to net income ratio is low.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue919.20M1.02B980.90M892.80M944.60M
Gross Profit142.40M164.60M176.90M109.10M90.50M
EBITDA-34.70M71.00M71.20M62.40M61.60M
Net Income-130.60M-189.70M-15.10M-15.80M-6.30M
Balance Sheet
Total Assets1.49B1.61B1.74B1.62B1.60B
Cash, Cash Equivalents and Short-Term Investments73.00M34.50M74.50M29.30M153.90M
Total Debt69.10M225.50M120.80M24.10M73.40M
Total Liabilities506.00M684.70M625.90M607.00M611.60M
Stockholders Equity983.50M927.70M1.11B1.01B989.40M
Cash Flow
Free Cash Flow14.90M-127.70M-122.60M-17.10M8.40M
Operating Cash Flow122.90M5.10M44.80M71.50M96.80M
Investing Cash Flow-108.00M-137.30M-167.40M-87.90M-88.30M
Financing Cash Flow26.50M92.20M187.80M26.50M-8.40M

Euroapi SA Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.94
Price Trends
50DMA
3.05
Negative
100DMA
2.86
Positive
200DMA
3.07
Negative
Market Momentum
MACD
-0.04
Positive
RSI
38.80
Neutral
STOCH
5.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EAPI, the sentiment is Negative. The current price of 2.94 is below the 20-day moving average (MA) of 3.06, below the 50-day MA of 3.05, and below the 200-day MA of 3.07, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 38.80 is Neutral, neither overbought nor oversold. The STOCH value of 5.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:EAPI.

Euroapi SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
€253.64M63.582.27%18.89%-20.75%
54
Neutral
€4.79B16.30-48.29%2.23%15.31%-8.27%
50
Neutral
€296.60M
-10.00%31.03%
42
Neutral
€35.77M
3.25%-2.07%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:EAPI
Euroapi SA
3.11
-0.24
-7.16%
FR:ALERS
Eurobio-Scientific SA
25.35
8.75
52.71%
FR:ALMDT
Median Technologies
1.90
-2.02
-51.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025